Th17 驱动的 CD8(+) T 细胞在 hUC-MSC 与 CAR-T 细胞双重免疫治疗中的卓越抗肿瘤疗效
Th17-driven CD8(+) T cells in hUC-MSC and CAR T-cell dual immunotherapy for superior anti-tumor efficacy.
80.9分
★★★★☆
站内排序·非疗效
ALL SOURCES
Th17-driven CD8(+) T cells in hUC-MSC and CAR T-cell dual immunotherapy for superior anti-tumor efficacy.
A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia.
A T-cell independent universal cellular therapy strategy through antigen depletion.
Multicellular Cancer-Stroma Spheres (CSS) for In Vitro Assessment of CAR-T Cell-Associated Toxicity.
Labial Gland Mesenchymal Stem Cell Derived Exosomes-Mediated miRNA-125b Attenuates Experimental Sjogren's Syndrome by Targeting PRDM1 and Suppressing
共 5 条
MEMBER ACCOUNT
登录成功会直接打开下一页。